TIGERMED - Overseas Regulatory Announcement - Articles Revision Comparison Table (August 2026)

HANGZHOU TIGERMED CONSULTING CO., LTD.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 3347)

Overseas regulatory announcement

This announcement is made by Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (the "Company") in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The announcement published by the Company on the Shenzhen Stock Exchange website is set out below for reference only.

By order of the board of directors

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Chairman

Ye Xiaoping

Hong Kong, August 28, 2026

As at the date of this announcement, the executive directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu; the employee directors are Mr. Wu Hao; and the independent non-executive directors are Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Xiao Yaoxi.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

Articles of Association Amendment Comparison Table

Serial number original terms revised terms

Article 6 The registered capital of the company is RMB. Article 6 The registered capital of the company is RMB 861,026,050. 855,142,270 yuan.

Article 23 The Company was approved by the China Securities Regulatory Commission on July 3, 2012 to issue 13.4 million RMB ordinary shares to the public for the first time (hereinafter referred to as "A shares"). (hereinafter referred to as "A shares").

The number of issued shares of the company is 861,026,050. The number of issued shares of the company is 855,142,270, all of which are ordinary shares. Among them, domestically listed domestic shares (A shares) are all ordinary shares, of which 737,901,250 are held by shareholders of domestically listed domestic shares (A shares). shareholders hold 732,017,470 shares, accounting for approximately 85.70% of the company's total capital stock; shareholders of overseas listed foreign shares (H shares) hold approximately 85.60% of the total capital; shareholders of overseas listed foreign shares (H shares) hold 123,124,800 shares, accounting for 123,124,800 shares of the company's total capital stock, accounting for approximately 14.30% of the company's total capital stock. The amount is approximately 14.40%.

Article 126 The Board of Directors shall consist of 7 directors. Article 126 The Board of Directors shall consist of 7 directors, including 1 Chairman, 1 Vice Chairman, and 1 independent director. There shall be 1 Chairman, 3 independent directors, 3 employee directors, and 1 employee representative director. At least one representative director shall be included. At least one of the independent directors must have appropriate accounting or relevant financial management expertise. long.

Article 163 The company shall have one general manager and two co-presidents, who shall be appointed or dismissed by the board of directors. There is one public co-president, who is appointed or dismissed by the board of directors. The company can have several deputy general managers, who are appointed by the board of directors; or the company can have several deputy general managers, who are appointed or dismissed by the board of directors. Dismissal.

Hangzhou Tigermed Pharmaceutical Technology Co., Ltd.

August 29, 2026